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ERAP1 promotes Hedgehog-dependent
tumorigenesis by controlling USP47-mediated
degradation of βTrCP
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The Hedgehog (Hh) pathway is essential for embryonic development and tissue homeostasis.
Aberrant Hh signaling may occur in a wide range of human cancers, such as medullo-
blastoma, the most common brain malignancy in childhood. Here, we identify endoplasmic
reticulum aminopeptidase 1 (ERAP1), a key regulator of innate and adaptive antitumor
immune responses, as a previously unknown player in the Hh signaling pathway. We
demonstrate that ERAP1 binds the deubiquitylase enzyme USP47, displaces the USP47-
associated βTrCP, the substrate-receptor subunit of the SCFβTrCP ubiquitin ligase, and pro-
motes βTrCP degradation. These events result in the modulation of Gli transcription factors,
the final effectors of the Hh pathway, and the enhancement of Hh activity. Remarkably,
genetic or pharmacological inhibition of ERAP1 suppresses Hh-dependent tumor growth
in vitro and in vivo. Our findings unveil an unexpected role for ERAP1 in cancer and indicate
ERAP1 as a promising therapeutic target for Hh-driven tumors.
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The Hedgehog (Hh) signaling pathway plays a crucial roleduring organogenesis and stem cells maintenance. Itsderegulation is responsible for the onset of several human
cancers1–5. Hh signaling is triggered by the binding of the Hh
ligand to the Patched1 (Ptch1) receptor, relieving the repression
on the Smoothened (Smo) co-receptor. This event leads activa-
tion of the Gli family transcription factors upon the dissociation
from SuFu protein, an important negative regulator of the
pathway2,6. In mammals, three Gli proteins have been identified:
Gli1 and Gli2 with activating functions and Gli3 mainly working
as repressor7. Ubiquitin-dependent proteolytic processing of Gli
transcription factors is important for controlling the Hh pathway
output. Of note, all Gli transcription factors undergo ubiquiti-
nation through β-transducin-repeat containing E3 ubiquitin
protein ligase (βTrCP), an F-box protein of the Skp1–Cul1–Fbox
protein (SCF) E3-ligase complex, which promotes the complete
degradation of Gli1 and Gli28–11, and the processing of Gli3 into
the repressor form Gli3R12–14. Deregulation of these events
results in uncontrolled cell proliferation and tumorigenesis9. One
of the most relevant Hh-dependent tumors is medulloblastoma
(MB), a highly aggressive pediatric malignancy arising from
cerebellar granule cell progenitors (GCPs) mainly mutated in
Ptch1 or Smo receptors15. The non-canonical Hh/Gli activation
regardless of the presence of mutated components of the pathway
or overexpression of the ligand is also frequently observed in MB
and other tumors. This emphasizes the importance of the
mechanisms controlling Gli activity, which are impaired in
disease16,17. Pharmacological inhibition of the Hh pathway has
been proposed as a therapeutic strategy in typical Hh-dependent,
tumors such as advanced basal cell carcinoma (BCC) and
medulloblastoma (MB)18,19. Hence, to identify novel Hh
antagonists we tested a number of small molecules and found
leucinethiol (Leu-SH), an inhibitor of Endoplasmic reticulum
aminopeptidase 1 (ERAP1)20–28, as one of Hh inhibitors.
ERAP1 is crucial for the maturation of a wide spectrum of
substrates involved in multiple biological processes, including
antigen processing and regulation of blood pressure and inflam-
mation29. Functional single nucleotide polymorphisms in ERAP1
have been associated with predisposition to several human dis-
eases, including autoimmune diseases, viral infections and virally-
induced cancer30. Reduction of ERAP1 expression by RNA
interference results in a drastic change in the repertoire of anti-
genic peptides presented by MHC class I molecules21,31,32. In
mouse models, the complete loss of ERAAP expression, the
mouse homologous of ERAP1, inhibits surface expression of
MHC class I molecules. In human neoplastic lesions, the
expression of ERAP1 differs as compared to the normal coun-
terparts, depending on the tumor type33. In general, loss of
ERAP1 is frequently associated with the lack of detectable MHC
class I surface expression, potentially contributing to tumor
immunoescape34. Consistently, in cervical carcinoma, altered
ERAP1 expression is linked to poor clinical outcome, suggesting
that an aberrant antigen processing may contribute to escape the
host immune surveillance35. Accordingly, inhibition of ERAP1
was shown to generate strong innate and adaptive anti-tumor
immune responses resulting in tumor regression in two distinct
tumor mouse models, thus providing evidences that modulation
of ERAP1 activity may represent a promising tool for cancer
immunotherapy27,36.
Here, we identified a role of ERAP1 in tumorigenesis, acting
through the activation of the Hh pathway. We demonstrate that
ERAP1 induces the degradation of βTrCP by physically inter-
acting with βTrCP-bound deubiquitylase enzyme USP47. This
event protects Gli transcription factors from βTrCP-dependent
degradation and stimulates Hh activity. Remarkably, both genetic
and pharmacological inhibition of ERAP1 suppresses Hh-
dependent tumor growth in vitro and in vivo, suggesting an
innovative therapeutic approach in the treatment of Hh-
dependent tumors.
Results
ERAP1 positively regulates the Hh pathway. While exploring
novel Hh antagonists we found Leu-SH27,28, an inhibitor of
ERAP120–28, as one of Hh inhibitors. Leu-SH significantly
reduced the luciferase activity of the Hh pathway-reporter in NIH
Shh-Light II cells activated via SAG treatment37 (Fig. 1a) but not
the one driven by Hh-unrelated or Hh-related signaling pathway
(i.e. Jun/AP1 and Wnt/β-Catenin, respectively) (Supplementary
Fig. 1). To explore the role of ERAP1 in the regulation of the Hh
pathway, we inhibited genetically or pharmacologically ERAP1 in
in vitro models. Following silencing of the murine ER amino-
peptidase ERAAP (herein referred as ERAP1) by means of short
hairpin RNAs and treatment with the Hh pathway agonist SAG38,
we observed a reduced expression of Gli1, the final and most
powerful effector of Hh signaling, both at mRNA and protein
levels (Fig. 1b, c). Consistent with these data, treatment with Leu-
SH of Ptch−/− mouse embryonic fibroblasts (MEFs), in which the
pathway is constitutively active39, induced a significant reduction
in the expression of several endogenous Hh target genes (Fig. 1d,
e). To investigate if ERAP1 is acting at post-receptor level, we
used SuFu−/− MEFs, in which the pathway is active due to the
loss of the well-known Gli inhibitor SuFu40. Leu-SH treatment
determined a downregulation of the Hh signature gene also in
this cellular context (Fig. 1f). Similar results were achieved fol-
lowing genetic ERAP1 depletion in both cell models (Fig. 1g, h),
indicating that ERAP1 promotes the Hh signaling acting down-
stream of SuFu.
ERAP1 activates Hh signaling by impairing βTrCP stability. To
better characterize the molecular mechanism whereby ERAP1
regulates the Hh pathway, we analyzed the protein levels of Gli
transcription factors in MEFs upon expression of increasing
amounts of ERAP1 (Fig. 2a). We observed that while Gli1 and
Gli2 were increased, both the full length and the cleaved form of
the Gli3 protein (Gli3FL and Gli3R, respectively) were reduced
(Fig. 2a). The opposite effect was observed following treatment
with increasing amounts of Leu-SH (Fig. 2b), which impairs the
enzymatic activity of ERAP1 without affecting its protein level
(Supplementary Fig. 2a). Of note, Leu-SH treatment was able to
antagonize the activation of Hh signaling induced by SAG,
leading to decreased expression of Gli1 and Gli2 and increased
levels of Gli3FL and Gli3R (Fig. 2c). Since ERAP1 did not directly
associate with Gli transcription factors (Supplementary Fig. 2b),
we hypothesized that ERAP1 could regulate βTrCP, an F-box
protein belonging to a Skp1/Cul1/F-box E3 ubiquitin ligase
complex crucial for the degradation of Gli19 and Gli28,10, and the
formation of Gli3R14,41,42. Dose-dependent overexpression of
ERAP1 led to reduction of βTrCP protein levels (Fig. 2d), whereas
its pharmacological or genetic inhibition resulted in the opposite
effect (Fig. 2e, f). Importantly, the reintroduction of ERAP1 in
ERAP1-knockdown cells downregulated βTrCP leading to
increased Gli1, to a lesser extend and Gli2 and decreased Gli3FL
and Gli3R levels (Fig. 2f). No change in βTrCP mRNA expression
was detected in both assays (Supplementary Fig. 3a, b). Impor-
tantly, the modulation of ERAP1 had no effect on other E3 ligases
involved in Gli ubiquitylation, such as Itch43,44, pCAF45, SPOP46
or SCF ubiquitin ligase Skp247 (Fig. 2d–f), as well as on other
βTrCP substrates48 (Supplementary Fig. 3c,d). Notably, ERAP1
did not affect Gli1 protein levels in the absence of βTrCP, indi-
cating that the latter is required for ERAP1-mediated regulation
of the Hh pathway (Fig. 2g). Moreover, βTrCP half-life was
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shorter following ERAP1 overexpression (Fig. 2h), suggesting that
ERAP1 controls βTrCP protein stability.
Next, we evaluated whether ERAP1 controls βTrCP levels by
modulating its ubiquitylation. To this purpose, we performed an
in vivo ubiquitylation assay upon ectopic expression of ERAP1.
High levels of ERAP1 promoted the poly-ubiquitylation of
endogenous βTrCP and its subsequent degradation by the
proteasome, leading to a significant accumulation of βTrCP
protein and its ubiquitylated forms in cells treated with the
proteasome-inhibitor MG132 (Fig. 2i). Conversely, βTrCP poly-
ubiquitylation was decreased in MEFs treated with increasing
amount of Leu-SH (Fig. 2j). As the phosphorylation of the Gli
transcription factors within the DSG(X)2+nS destruction motifs
(degron) is required for the interaction of βTrCP9,41,49, we
evaluated if the effect of ERAP1 depended upon the presence of
this motif. To this purpose, MEFs were transfected with the wild
type (HA-Gli1 WT) or the mutant (HA-Gli1ΔC) form of Gli1
lacking the degron essential for βTrCP recognition9, and then
treated with increasing amount of Leu-SH. Inhibition of ERAP1
induced a reduction in the levels of the wild type, but not of the
mutated form of Gli1 (Fig. 2k). The same result was obtained in
MEFs transduced with shCTRL or shERAP1 (Fig. 2l). Interest-
ingly, we also observed that Gli1 is phosphorylated in Ptch−/−
MEFs by Phospho-Kinase A (PKA) (Supplementary Figure 4), the
kinase that triggers the phosphorylation cascade of Gli transcrip-
tion factors required for βTrCP recognition, being increased after
treatment with PKA inhibitor50,51.
Altogether these data demonstrate that ERAP1 promotes Hh
pathway activity by impairing βTrCP protein levels leading to the
modulation of Gli proteins.
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Fig. 1 ERAP1 positively regulates the Hh pathway at postreceptor level. a Luciferase activity of NIH3T3 Shh-Light II cells treated for 24 h with SAG and
increasing amounts of Leu-SH or DTT as control. b, c Quantitative real-time PCR (qRT-PCR) (b) and representative immunoblotting (c) analyses of Gli1
expression in the NIH3T3 murine fibroblasts transduced with lentiviral vectors encoding either control shRNA (shCTRL) or ERAP1 shRNA (shERAP1#1 and
shERAP1#2) and treated with SAG or DMSO for either 24 or 48 h. In c ERAP1 expression was also evaluated and actin was used as loading control.
d, f qRT-PCR analysis of Hh target genes expression in Ptch−/− (d) and SuFu−/− MEFs (f) both treated with Leu-SH (30 μM) or DTT as control.
e Representative model of the constitutive activation of Smo or Gli1 in Ptch−/− and SuFu−/− MEFs, respectively. g, h qRT-PCR analysis of Hh target genes
expression in Ptch−/− (g) and SuFu−/− MEFs (h) transduced with shCTRL or shERAP1 constructs. Data in b, d, f, g, and h are normalized to endogenous
GAPDH and HPRT controls and expressed as the fold change respect to the control sample value. All data represent the mean of three independent
experiments. Mean ± SD; *P < 0.05; **P < 0.01; ***P < 0.001 calculated with two-sided Student’s t-test
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ERAP1 promotes βTrCP degradation by interacting with
USP47. As ERAP1 did not appear to interact directly with βTrCP
(Supplementary Figs. 5a, b), we investigated whether ERAP1
interferes with the Ubiquitin-Specific Protease 47 (USP47), a
deubiquitylating enzyme known to interact with βTrCP52.
Co-immunoprecipitation experiments demonstrated that
ERAP1 binds both exogenous and endogenous USP47 in MEFs
(Fig. 3a–d). Accordingly, confocal microscopy revealed that
ERAP1 co-localizes with endogenous USP47 proteins in the
perinuclear region, where endogenous ERAP1 is mainly loca-
lized31 (Fig. 3e). Further, ERAP1 did not bind other Ubiquitin-
Specific Proteases known to regulate the stability or activity of
βTrCP, such as USP2453 and USP2254 (Supplementary Fig. 5c).
βTrCP stability was impaired in USP47−/− MEFs, leading to
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increased expression of Gli1 and Gli2 and decreased expression
of Gli3FL and Gli3R (Fig. 3f). Consistently, the re-introduction
of USP47 in USP47−/− MEFs restored βTrCP protein levels
(Fig. 3g). Moreover, βTrCP half-life was reduced in the USP47−/−
MEFs (Fig. 3h) and increased in the presence of USP47 as com-
pared to control cells (Fig. 3i). Of note, USP47 overexpression
decreased Gli1 half-life (Fig. 3j) in agreement with the established
role of βTrCP in Gli1 regulation.
The effect of USP47 on ERAP1-mediated βTrCP ubiquitylation
was studied by performing an in vivo βTrCP ubiquitylation assay
in the presence of ectopic expression of ERAP1 and/or USP47.
High levels of ERAP1 promoted a robust ubiquitylation of βTrCP
that was counteracted by the co-expression of USP47 (Fig. 3k).
Accordingly, the overexpression of USP47 alone leads to a
decrease of ubiquitylated βTrCP (Fig. 3k) consistent with the
enzymatic function of USP4752. Importantly, ERAP1 strongly
impaired βTrCP/USP47 interaction (Fig. 3l), whereas its
pharmacological inhibition or genetic depletion resulted in an
increased association between the two proteins (Fig. 3m, n).
Overall, these findings indicate that ERAP1 promotes ubiqui-
tylation and degradation of βTrCP by displacing its interaction
with the USP47 deubiquitylase enzyme.
ERAP1 affects Hh-dependent growth of cerebellar GCPs. Hh
signaling crucially regulates cerebellar development by controlling
the expansion of a subset of granule cell progenitors (GCPs) and
the proper development of the granule neuron lineage under
Purkinje cell-derived Shh stimuli. Withdrawal of Hh signal causes
physiologically GCPs growth arrest after the first post-natal week
in mice inducing their differentiation into mature granules55.
Importantly, genetic or epigenetic alterations in the Hh signaling
lead to GCPs increased proliferation and their tumorigenic
conversion56,57. To investigate the biological role of ERAP1 on
Hh-dependent growth, the levels of ERAP1 expression were
analyzed in GCPs at an early post-natal stage that is Hh-
dependent. Similar to Gli1, ERAP1 was mainly expressed in the
Hh-dependent outer external germinal layer (EGL) where highly
proliferating GCPs reside, and absent in non-proliferating inner
germinal layer (IGL) GCPs (Fig. 4a). Consistently, the prolifera-
tion rate and Gli1 expression levels of SAG-treated GCPs were
significantly reduced in the presence of high doses of Leu-SH
(Fig. 4b, c) or following the genetic inhibition of ERAP1
(Fig. 4d–f). As expected, the opposite effect was observed in SAG-
treated GCPs overexpressing ERAP1 (Fig. 4g–i), suggesting a
potential role of ERAP1 in controlling GCPs proliferation
through Hh signaling.
ERAP1 affects Hh-dependent tumor cell growth in vitro. GCPs
are considered the cells of origin of MB, the most common
pediatric brain tumor genetically classified in four subgroups, of
which Shh-group is the best characterized1,58. The relevance of
ERAP1 on Hh-dependent tumor cell growth was determined by
testing short-term cultures of primary MB cells freshly isolated
from Math1-cre/PtcC/C mice tumors, one the most used model to
study the Hh-dependent tumorigenesis39,57,59–61. Pharmacologi-
cal inhibition of ERAP1 significantly reduced the proliferation of
Math1-cre/PtcC/C MB cells in a dose- and time-dependent
manner (Fig. 5a). This was consistent with increased cell death
(Fig. 5b), increased levels of the cleaved Caspase 3 protein
(Fig. 5c) and reduced BrdU uptake (Fig. 5d). Accordingly, Gli1
expression was reduced at mRNA and protein levels (Fig. 5e, f),
indicating an impairment of the Hh signaling activity. Given the
difficulty to obtain stable Hh-dependent MB cell lines, tumor cells
from spontaneous MB of Math1-cre/PtcC/C mice were propa-
gated as neurospheres (MB Stem-Like Cells, MB-SLCs) in EGF-
and bFGF-free cultured medium to retain the characteristic of
in vivo Hh-subtype MB and preventing the differentiation of
GCPs62. Similarly to cerebellar progenitors, the pharmacological
inhibition of ERAP1 impaired both tumor cell proliferation in a
dose- and time-dependent manner (Fig. 5g) and clonogenic self-
renewal ability (Fig. 5h). Accordingly, MB neurospheres treated
with increasing amounts of Leu-SH showed an impaired Hh
pathway activity as evaluated by the significant reduced expres-
sion of the Hh pathway target genes Gli1, Gli2, and Ptch1,
stemness markers (Oct4 and Nanog) and growth (CycD2) and
oncogenic (N-Myc) related signals (Fig. 5i, j). Overall, these data
demonstrate that ERAP1 affects Hh-dependent MB cell
proliferation.
ERAP1 affects Hh-dependent tumor growth in vivo. Based on
the in vitro studies, we hypothesized that inhibition of ERAP1
activity may reduce tumor growth in vivo. To address this
critical issue NOD/SCID gamma (NSG) mice were grafted with
spontaneous primary MB from Math1-cre/PtcC/C mice and the
obtained tumor masses were treated with Leu-SH or vehicle
for about three weeks27. Leu-SH treatment significantly
reduced tumor growth as compared to controls (Fig. 6a, b).
Reduced cellularity associated with a decreased Ki67 and
increased NeuN and cleaved Caspase-3 positive tumor cells was
detected in Leu-SH treated tumor masses, indicating that
ERAP1 inhibition impairs tumor growth by promoting cell
differentiation and committing tumor cells to apoptosis
(Fig. 6c, d). In agreement with the in vitro data (Fig. 5), the
Fig. 3 ERAP1 promotes βTrCP ubiquitylation by interacting with USP47. a–d MEFs were transfected with ERAP1 and/or Flag-USP47. Interaction between
USP47 and ERAP1 was detected by immunoprecipitation followed by immunoblot analysis with the indicated antibodies. e MEFs transfected with ERAP1
were stained with anti-ERAP1 and anti-USP47 antibodies. Green and red, USP47 and ERAP1 expressing cells, respectively. Nuclei were counter stained with
Hoechst (Blue). Magnification ×60; Bars: 5 μm. Representative images from three independent experiments. f βTrCP and Gli steady state in USP47+/+ and
USP47−/− MEFs. g βTrCP protein level in USP47+/+, USP47−/− and USP47−/− Flag-USP47 transfected MEFs. h βTrCP half-life in USP47+/+ vs.
USP47−/− MEFs treated with CHX (100 µg/mL) at the indicated times. i βTrCP protein levels in MEFs transfected with empty vector as control or
Flag-USP47 and treated with CHX (100 µg/mL) at different time points. j Gli1 protein levels in Ptch−/− MEFs transfected with empty vector as control or
Flag-USP47 and treated after 24 h with CHX (100 µg/mL) for different time points. In g–j densitometric analysis of βTrCP and Gli1 protein levels of three
independent experiments are shown (right panels). k MEFs were transfected with HA-Ub and increasing amount of ERAP1 in the presence or absence of
Flag-USP47. Endogenous βTrCP was immunoprecipitated with an anti-βTrCP antibody and the ubiquitylated forms were revealed with an anti-HA antibody
(upper panel). The blot was reprobed with an anti-βTrCP antibody. Flag-USP47, ERAP1 and βTrCP total protein levels are shown (lower panel). l MEFs
were transfected with Flag-USP47 and increasing amount of ERAP1. Interaction between Flag-USP47 and endogenous βTrCP was assessed by
immunoprecipitation and immunoblotting with the indicated antibodies. Actin was used as loading control. m MEFs were transfected with Flag-USP47 and
treated for 24 h with Leu-SH at the indicated concentration. Interaction between Flag-USP47 and endogenous βTrCP was detected as described in
l. Densitometric analysis of the Flag-USP47/βTrCP binding ratio representative of three independent experiments is shown (right panel). n MEFs
were transduced with shCTRL or shERAP1 and transfected with Flag-USP47. Interaction between Flag-USP47 and endogenous βTrCP was assessed
as described in l
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expression of endogenous Hh target genes was reduced at both
mRNA and protein levels in Leu-SH-treated tumors compared
to controls, whereas protein levels of NeuN, cleaved Caspase-3
and βTrCP were increased (Fig. 6e, f). An orthotopic allograft
animal model in which primary MB cells isolated from Math1-
cre/PtcC/C mice tumors were implanted into the cerebellum of
NSG mice confirmed these results. The animals treated with
Leu-SH showed a significant reduction of tumor masses as
compared to control (Fig. 6g, h). Accordingly, in a further
allograft model all mice engrafted on the flanks with MB cells
infected with control lentiviruses developed progressively
enlarging tumors, whereas no palpable tumor masses were
developed in most mice engrafted with MB cells infected with
shERAP1 lentiviruses (Fig. 6i, j). Consistent with above data,
these tumor masses showed a reduced cellularity with few MB
cells dispersed in a large amount of Masson’s staining-mediated
blue-labeled connective tissue and reduced Hh-pathway sig-
nature, as compared to control tumors (Fig. 6k, l). A more
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robust effect of the ERAP1 function on the MB in vivo cell
growth was observed in an orthotopic allograft model where
spontaneous primary MB cells from Math1-cre/PtcC/C mice
genetically silenced for ERAP1 were implanted into the cere-
bellum of NSG mice. As shown in Fig. 6m, only the cells
infected with the lentiviral particles encoding for a non-
targeting sequence gave rise to detectable tumor masses. These
findings demonstrate that inhibition of ERAP1 interferes with
Hh-dependent MB growth processes in vivo.
To investigate the role of ERAP1 during MB development,
tumor-prone GCPs from the cerebellum of five-day postnatal
(P5) Math1-cre/PtcC/C mice were infected with lentiviruses
expressing ERAP1 and then injected into the flank of NSG
recipient animals. Compared to controls, mice engrafted with
GCPs overexpressing ERAP1 showed an increased tumor growth
rate, tumor volume (at the end point), and expression of Gli1 and
CyclinD2 (Fig. 6n–p), accordingly with the role of ERAP1 in
promoting Hh signaling.
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Moreover, to verify the effect of ERAP1 inhibition in a natural
tumor niche for MB growth, symptomatic Gfap-cre/Ptcfl/fl mice
were treated with Leu-SH or vehicle for two consecutive days.
Treatment with Leu-SH resulted in reduced levels of the Hh
pathway target genes and increased levels of βTrCP (Supplemen-
tary Figs. 6a, b). Interestingly, we found that i.p. treatment with
Leu-SH significantly improved survival in the Math1-cre/PtcC/C
(Fig. 6q), demonstrating the potential therapeutic benefit of
ERAP1 inhibition in the development of tumors in situ.
Together, these data identify a molecular mechanism in the
regulation of Hh signaling and unveil the relevance of ERAP1 in
the control of Hh-dependent tumor growth.
ERAP1 inhibition impairs human SHH-MB growth. Next,
we investigated the effect of the inhibition of ERAP1 in human
SHH-MB models. Similarly to murine tumor models, either
pharmacological or genetic inhibition of ERAP1 impairs in vitro
proliferation of the human Hh-dependent MB cell line Daoy
(Supplementary Fig. 7a, b, d, e), leading to a decreased Hh-
pathway activity (Supplementary Fig. 7c, f, g). To further evaluate
the effect of ERAP1 activity in vivo, we performed a xenograft in
NSG mice grafted on the flank with Daoy cells infected with
lentiviral particles encoding for either shERAP1 or shCTRL. As
expected, inhibition of ERAP1 significantly reduced tumor
growth compared to controls, resulting in a decrease in
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endogenous Hh target genes at both mRNA and protein levels
(Supplementary Figs. 7h–k).
Finally, we found that the pharmacological inhibition of
ERAP1 affected SHH-MB Patient-Derived Xenograft (PDX)63
cell proliferation and increased tumor cell death in a dose- and
time-dependent manner leading to apoptosis, as indicated by
increased cleaved Caspase-3 positive cells (Fig. 7a–e). These
results were confirmed by evaluating the cellular confluence over
time of the SHH-MB PDX cells treated with increased amounts of
Leu-SH (Supplementary Figs. 8a–c). As expected, the genetic
depletion of ERAP1 in SHH-MB PDX cells resulted in reduced
cell proliferation, increased cell death and reduced levels of Gli1
protein (Supplementary Figs. 8d–g).
In agreement with the in vitro data, Leu-SH treatment reduced
the growth of MB SHH-PDX cells injected into the flank of NSG
mice (Fig. 7f, g). As in the allograft model performed with
spontaneous murine tumor (Fig. 6a–f), tumor masses treated with
Leu-SH showed a reduced cellularity associated with a decrease in
Ki67-positive tumor cells and an increase in NeuN and cleaved
Caspase-3 positive tumor cells (Fig. 7h, i). Moreover, mRNA and
protein expression levels of the endogenous Hh target genes were
reduced, unlike the βTrCP protein levels (Fig. 7j, k). Overall, these
data confirm the role of ERAP1 in the regulation of Hh-
dependent tumor growth.
Discussion
Hh signaling is an evolutionarily conserved pathway regulating
cell fate and specification. Its tight regulation is essential for
proper development and adult tissue preservation. Constitutive
activation of the Hh pathway has been associated with a multi-
tude of cancer types, including brain tumors. Hh signaling is also
known to regulate stemness and drive tumor initiation and
progression64. Due to its crucial role in tumorigenesis, Hh sig-
naling has emerged as an attractive druggable target and a
number of pathway-specific inhibitors are moving into the
clinic65,66. However, therapeutic strategies aiming at blocking Hh
signaling activation are complicated by the development of
resistance and side effects, thus prompting alternative treatment
approaches.
The combination of multiple drugs targeting different Hh
signaling components and/or correlating Hh activating routes
represents the most effective strategy for cancer treatment67–72.
For this reason, the identification of molecular players controlling
Hh activity is of clinical importance and represents a dramatic
challenge in tumor biology.
In the present study, we identify and characterize an oncogenic
property of ERAP1, an endoplasmic reticulum aminopeptidase. So
far, ERAP1 has been well-studied for its role in the antigen pro-
cessing, a mechanism resulting in the production of high affinity
peptides for the binding to MHC class I molecules. Like the other
components of the antigen processing machinery, ERAP1 is
induced in response to IFN-γ stimulation22, a feature that makes it
particular active in counteracting antiviral and anti-tumor immune
responses. In this context, ERAP1 trims the N-terminal extension of
precursor peptides to generate mature antigenic peptides21. Loss of
ERAP1 function results in the generation of a new immunopepti-
dome, which stimulates anti-tumor immune responses determining
the tumor regression of different mouse models27,36. Moreover,
recent genome-wide studies have strongly associated ERAP1 poly-
morphisms with several autoimmune diseases, such as ankylosing
spondylitis29. The polymorphic residues map to ERAP1’s catalytic
and regulatory sites and alter peptide specificity and processing
activity, thus suggesting that the enzymatic activity of ERAP1 is
important in the link with genetic disease30. However, the lack of
commercial availability for highly specific chemical compounds for
ERAP1 has constrained the progress in this area. Given the great
interest in ERAP1, many pharmaceutical companies are investing in
the development of ERAP1 inhibitors for potential therapeutic
intervention.
Herein, we uncovered an unexpected role of ERAP1 in reg-
ulating Hh-dependent tumorigenesis, thus providing further
evidence that inhibition of ERAP1 may be exploited for cancer
treatment. We demonstrated that ERAP1 enhances Hh activity by
sequestering USP47 and promoting ubiquitylation and degrada-
tion of βTrCP. This event results in an increase of Gli1 and Gli2
protein levels and a reduction of the Gli3R form, thus activating
the Hh pathway and stimulating cell proliferation and tumor-
igenesis (Fig. 8). Conversely, inhibition of ERAP1 function sta-
bilizes βTrCP, which in turn induces ubiquitylation of Gli factors
leading to proteolysis of Gli1 and Gli2 and generation of Gli3R,
thereby suppressing tumor cell growth.
Gli transcription factors are crucial effectors of the Hh pathway
and their activity and expression are finely regulated by several
mechanisms, mainly by the ubiquitin-proteasome system. Upon
phosphorylation by PKA, GSK3β, and CK1, Gli factors are
recognized by the SCFβTrCP ubiquitin ligase, which triggers the
proteasome-dependent degradation of Gli19 and processing of
Gli3 in its repressor form14,41. Gli2 is processed by both events,
although the degradation one being predominant8,10. Hence,
inhibition of the βTrCP-mediated degradation of Gli proteins is
part of an Hh-induced activation signal by which Hh supports the
function of Gli. Although βTrCP is fundamental for the regula-
tion of Hh-mediated signals, the mechanisms controlling its
function are still largely unexplored.
Fig. 6 ERAP1 inhibition impairs Hh-dependent tumor growth in vivo. a–f NSG mice were grafted with spontaneous primary MB from Math1-cre/PtcC/C
mice. Tumor masses (150mm3) were intratumorally injected with Leu-SH. a Tumor growth was monitored. b Representative flank allograft average
volumes (lower panel) and quantification of tumor explants (upper panel). c, d Ki67, NeuN, and cleaved Caspase-3 (Cl.Casp-3) immunohistochemical
stainings of allograft tumor samples. d Quantification of immunohistochemical stainings shown in c. Scale bar 100 μm. e mRNA and f protein expression
levels of Hh targets from tumors assayed in b. g Representative H&E images (low and high magnification) of a murine MB cell-derived orthotopic tumor in
NSG mice after i.p. injection of Leu-SH. Scale bars, 500 μm and 200 μm (upper and lower panels, respectively). h Representative average volume of
orthotopic tumor. i–j NSG mice were grafted with spontaneous primary MB from Math1-cre/PtcC/C mice genetically silenced for ERAP1 expression.
i Representative images of mice and the explanted tumor masses. j Quantification of the flank allograft average tumor volume. ERAP1 protein expression is
shown below. In f, j, actin was used as loading control. k H&E and representative Masson’s trichrome staining of tumors. Scale bar 100 μm. l mRNA levels
of the indicated Hh target genes. m Representative H&E images (low and high magnification) of a murine MB cell-derived orthotopic tumor genetically
interfered for ERAP1 before the injection in NSG mice cerebella. Scale bars, 500 and 200 μm (upper and lower panels, respectively). n–p ERAP1 accelerates
Hh-MB formation. n Tumor volume of mice subcutaneously transplanted with GCPs from tumor-prone Math1-cre/PtcC/C animals overexpressing ERAP1.
o Representative flank allograft average volumes (lower panel) and quantification of the explanted tumor masses (upper panel). p mRNA expression of Hh
target genes from the tumor masses assayed in o. q Survival curves of Math-cre/PtcC/C mice treated with Leu-SH or vehicle. Results in e, l, p were
normalized to endogenous GAPDH and HPRT controls and expressed as in Fig. 1. All data represent the mean of three independent experiments. Mean ±
S.D. of tumor (n= 6) for each treatment. *P < 0.05, **P < 0.01, *** P < 0.001 calculated by two-sided Student’s t-test
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USP47 is a member of a class of enzymes named Ubiquitin-
Specific Proteases (USPs), which are able to catalyze the removal
of ubiquitin from substrates counteracting the activity of E3
ubiquitin ligases or protect them from self-ubiquitylation/degra-
dation events.
Previous reports have demonstrated that USP47 is a key player
in the regulation of cell viability and maintenance of genome
integrity by promoting the stability of DNA polymerase β52,73.
USP47 has been also described as a βTrCP interactor, although
the biological outcome of this interaction is controversial52,74.
Here, we found that USP47 strongly stabilizes βTrCP preventing
its ubiquitin-dependent degradation. Interestingly, this process is
inhibited by ERAP1 that, through the binding to USP47, hampers
the βTrCP/USP47 interaction and induces βTrCP proteolysis.
Consequently, the Hh pathway is triggered by the transcription
factors Gli, which promote cell proliferation. These results also
provide convincing evidence that USP47 impairs Hh/Gli signal-
ing and the Hh-driven tumorigenesis. Interestingly, no difference
in ERAP1 and USP47 expression levels was observed in SHH MB
as compared to other molecular subgroup or other brain tumor
entities (Supplementary Fig. 9), thus suggesting that the activity,
rather than the expression, of ERAP1 could be related to the
SHH-MB. This adds more complexity due to the presence of
modulators or not yet identified ERAP1 polymorphisms that
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Fig. 7 a–e SHH-MB PDX tumor cells were treated with different amounts of Leu-SH. a, b Cells were counted with trypan blue at the indicated time points
to evaluate the growth rate of viable cells (a) and the percentage of cell death (b). c Cell survival was also assessed by the Cell Titer Glo assay.
d Immunofluorescent staining of cleaved Caspase 3 (green) of Leu-SH treated cells (48 h). Nuclei were counter stained with Hoechst (Blue). Scale bar
5 μm. e Quantification of cleaved Caspase-3 from immunofluorescence stainings in (d). (f–k) NSG mice (n= 6 for group) were grafted with SHH-MB PDX
tumor cells. Tumor masses (150mm3) were intratumorally injected with Leu-SH (0.528 μM/Kg). f Tumor growth was monitored every three days.
g Quantification of the explanted tumor masses (upper panel) and representative flank xenograft average volumes (lower panel). h H&E, Ki67, NeuN and
cleaved Caspase-3 immunohistochemical staining of PDX tumor samples. i Quantification of Ki67, NeuN and cleaved Caspase-3 from
immunohistochemical stainings in h. Scale bar 100 μm. j, k mRNA (j) and protein (k) expression levels of the indicated Hh target genes from the tumor
masses assayed in g. Mean ± S.D. *P < 0,05; **P < 0,01; ***P < 0,001; ****P < 0,0001 determined using two-tailed Student’s t-test
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could alter its conformational state and induce defects in its open-
close transitions75, thus modifying the activity of ERAP1 or its
binding affinity to other proteins (i.e. to favor interaction with
USP47 that leads to the degradation of βTrCP and stability of Gli
proteins).
In conclusion, our study reveals an unexpected function of
ERAP1 in cancer development suggesting that targeting ERAP1
could open innovative perspectives for effective therapeutic
approaches in the treatment of Hh-dependent tumors.
Methods
Cell cultures, transfections, and lentiviral infections. NIH3T3 cells, Shh-Light-
II cells and MEFs from wild-type (WT) or Ptch−/−, SuFu−/−, USP47+/+ and
USP47−/− mice were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM)
plus 10% fetal bovine serum (FBS) or 10% bovine serum (BS) for NIH3T3 cells.
Daoy cells were cultured in Eagle’s minimum essential medium (MEM) plus 10%
FBS. All media contained L-glutamine and antibiotics. HEK293T (CTR-3216TM)
and NIH3T3 (CRL-1658TM) cells were obtained from ATCC. SuFu–/– MEFs were
gift from Dr. R. Toftgård (Karolinska Institute), Ptch−/− MEFs were gift from Dr.
M. P. Scott (Stanford, California, USA). For cerebellar GCPs culture from 4-days-
old mice, cerebella were removed aseptically, cut into small pieces, and incubated at
room temperature for 15 min in digestion buffer [Dulbecco’s PBS (Invitrogen,
Gaithersburg, MD) with 0.1% trypsin, 0.2% EDTA, and 10 μg/ml DNase]. Tissues
were then triturated with fire-polished Pasteur pipettes to obtain a single-cell
suspension. Cells were centrifuged and resuspended in Neurobasal medium sup-
plemented with B27 (2%), penicillin–streptomycin (1%) and L-glutamine (1%)
(Invitrogen) and plated at a density of 8 × 105 cells/cm2. Primary MB cells were
freshly isolated from Ptch+/− mice. Briefly, tumor was mechanically disrupted with
fire-polished Pasteur pipettes in HBSS with 1% Pen/Strep and treated with DNase
(10 μg/ml) for twenty minutes. Cells were centrifuged and resuspended in Neu-
robasal Media-A with B27 supplement minus vitamin A, penicillin–streptomycin
(1%) and L-glutamine (1%). Stable Hh-dependent MB cells were cultured as neu-
rospheres in DMEM/F12 media (2% B27 minus vitamin A; 3% Glucose 10×; 0.2%
Insulin 10 mg/ml; 1% Pen/Strep; 0.01% Heparin 2 mg/ml; 0.06% N-Acetyl-L-
Cysteine).
Mycoplasma contamination in cell cultures was routinely detected by using
PCR detection kit (Applied Biological Materials, Richmond, BC, Canada).
Transient transfections were performed using DreamFectTMGold transfection
reagent (Oz Biosciences SAS, Marseille, France), or Lipofectamine® with PlusTM
Reagent (Thermo Fisher Scientific, Waltham, MA, USA) in accordance with the
manufacturer’s protocols.
Lentiviral particles were generated in HEK293T cells by combining packaging
plasmids pCMV-dR8.74 and VSV-G/pMD2, with pLKO.1 plasmid (shCTRL
SHC002; shERAP1 TRCN0000031119 (#1), TRCN0000031121 (#2),
TRCN0000060542 (for Daoy and PDX), Sigma-Aldrich) or TWEEN-ERAP1 and
its empty vector, using TransIT-293 transfection reagent (MIRUS Bio LLC,
Madison, WI, USA). NIH3T3, MEFs and Daoy cells were infected by spin
inoculation method. Primary MB cells were infected with purified lentiviruses
for 72 h.
For RNA interference, cells were transfected with scrambled or βTrCP shRNAs
(Cat no: D-001810-10-05 and E-044048-00, respectively, Dharmacon, Inc.,
Lafayette, CO, USA) for 48 h with HiPerFect transfection reagent (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions.
Plasmids, Antibodies and other reagents. pcDNA3.1-Flag-USP47, pcDNA3-
Flag-Gli1, pcDNA3-Flag-Gli2, and pcDNA3-Flag-Gli3 were generated in our lab
with standard cloning techniques and verified by sequencing. pCS2HA3hGli1 WT
and pCS2HA3hGli1ΔC were kindly provided by A.E. Oro. pCMV6-XL5-ERAP1
(SC311137) was purchased from Origene (Rockville, MD, USA). shCTRL
(SHC002) and shERAP1 (TRCN0000031119, TRCN0000031121,
TRCN0000060542) in pLKO.1 plasmids were purchased from Sigma-Aldrich.
ERAP1 transcript variant 2 was cloned in the lentiviral vector pRRL-CMV-PGK-
GFP-WPRE (TWEEN) under the control of the CMV promoter.
Mouse anti-Gli1 (L42B10, 1:500), rabbit anti-βTrCP (D13F10, 1:1000), rabbit
anti-cleaved Caspase-3 (Asp175 D3E9, 1:100 for IHC, 1:500 for WB) and rabbit
anti-Phospho-PKA Substrate (RRXS*/T*, 100G7E, 1:1,000) were purchased from
Cell Signaling (Beverly, MA, USA). Mouse anti-α Tubulin TU-02 (sc-8035, 1:1000),
goat anti-Actin I-19 (sc-1616, 1:1,000), mouse anti-βTrCP C-6 (sc-390629, 2 μg),
mouse anti-HA-probe F-7 HRP (sc-7392 HRP, 1:1,000), mouse anti-pCAF E-8 (sc-
13124, 1:500), rabbit anti-Cyclin D1-20 (sc-717, 1:500), mouse anti-N-Myc B8.4.B
(sc-53993, 1:500), rabbit anti-Gli1 H300 (sc-20687, 1:100) and HRP-conjugated
secondary antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). Anti-Flag M2 HRP (A8592, 1:1000) and rabbit anti-Flag (F7425, 2 μg)
were purchased from Sigma Aldrich (St Louis, MO, USA). Rabbit anti-USP47
(A301-048A, 1:1000, 2 μg) from Bethyl Laboratories (Montgomery, TX, USA).
Mouse anti-SKP2 (323300, 1:500) were purchased from Invitrogen (Thermo Fisher
Scientific, Waltham, MA, USA). Goat anti-Gli3 (AF3690, 1:1000) and goat anti-
Gli2 (AF3635, 1:1000) were from R&D Systems (Minneapolis, MN, USA). Mouse
anti-ERAP1 6H9 (1:1000) and mouse anti-ERAP1 4D2 (2 μg), kindly provided by
P. van Endert, recognize denatured and native human ERAP1, respectively. Mouse
anti-Itch (611199, 1:1000) antibody was purchased from BD Bioscience
(Heidelberg, Germany). Rabbit anti-SPOP (16750-1-AP, 1:1000), Rabbit anti-
USP22 (55110-1-AP, 1:2000) and Rabbit anti-USP24 (13126-1-AP, 1:1000) were
purchased from Proteintech (Thermo Fisher Scientific, Waltham, MA, USA).
Rabbit anti-Ki67 SP6 (MA5-14520, 1:100) was from Thermo Fisher Scientific
(Waltham, MA, USA). Anti-rabbit Alexa Fluor 488 (A21206, 1:400 in BSA 3%) and
anti-mouse Alexa Fluor 546 (A11003, 1:400 in BSA 5% and Goat Serum 3%) were
purchased from Life Technologies (Foster City, CA, USA). Mouse anti-NeuN
(clone A60, MAB377, 1:100 for IHC and 1:1000 for WB) was from Millipore
(Merk, Darmstadt, Germany).
Where indicated, cells were treated with SAG (200 nM, Alexis Biochemicals
Farmingdale, NY, USA) for 24 or 48 h, MG132 (50 µM; Calbiochem, Nottingham,
UK) for 4 h, Cycloheximide (CHX 100 µg/ml, Sigma Aldrich), Dihydrochloride (H-
89, Calbiochem, Nottingham, UK), L-Leucinethiol (Leu-SH, Sigma Aldrich) or
Dithiothreitol (DTT, SERVA, Heidelberg, Germany) as indicated.
Luciferase reporter assay. The Hh-dependent luciferase assay was performed in
Shh-Light II cells, stably expressing a Gli-responsive luciferase reporter and the
pRL-TK Renilla (normalization control), treated for 48 h with SAG (200 nM) and
for 24 h with Leu-SH and/or DTT as control at the indicated concentrations.
AP1/Jun- and WNT/β-Catenin-luciferase assays were carried out in MEFs WT
transfected with MMP1-luciferase reporter and Jun- or Top Flash-luciferase
reporter and β-Catenin, respectively, and pRL-TK Renilla. After 24 h from
transfection, cells were treated with increasing amounts of Leu-SH and/or DTT.
Luciferase and Renilla activities were assayed with a dual-luciferase assay system
according to the manufacturer’s instructions (Biotium Inc., Hayward, CA, USA).
Results were expressed as luciferase/Renilla ratios and represented the mean ± S.D.
of three experiments, each performed in triplicate.
Immunoblot analysis and immunoprecipitation. Cells were lysed in a solution
containing RIPA buffer (50 mM Tris-HCl at pH 7.6, 150 mM NaCl, 0.5% sodium
deoxycholic, 5 mM EDTA, 0.1% SDS, 100 mM NaF, 2 mM NaPPi, 1% NP-40)
supplemented with protease and phosphatase inhibitors. The lysates were cen-
trifuged at 13,000 g for 30 min at 4 °C and the resulting supernatants were sub-
jected to immunoblot analysis. Immunoprecipitation was performed using whole-
cell extracts obtained by lysing cell pellets with Triton Buffer (50 mM Tris-HCl pH
7.5, 250 mM sodium chloride, 50 mM sodium fluoride, 1 mM EDTA pH 8, 0.1%
Triton), supplemented with protease and phosphatase inhibitors. Cell lysates were
immunoprecipitated overnight at 4 °C with rotation with specific primary anti-
bodies or IgG used as a control (1–2 µg/ml, Santa Cruz Biotechnology) and then
incubated with Protein G- or Protein A-agarose beads (Santa Cruz Biotechnology)
for 1 h at 4 °C with rotation. The immunoprecipitates were then washed five times
with the lysis buffer described above, resuspended in sample loading buffer, boiled
for 5 min, resolved in SDS-PAGE and then subjected to immunoblot analysis.
Hh activation Hh inhibition
Cell growth
tumorigenesis
Growth arrest
Fig. 8 A representative model showing the role of ERAP1 in Hh-dependent
tumorigenesis. ERAP1 promotes ubiquitylation and proteasomal
degradation of βTrCP by sequestering USP47. This event leads to increase
of Gli1 and Gli2 protein levels and decrease of Gli3R, thus triggering the Hh
pathway and favoring cell growth and tumorigenesis. In the absence of
ERAP1, USP47 binds and stabilizes βTrCP, which, in turn, promotes
ubiquitylation and proteasomal degradation of Gli1 and Gli2, and
ubiquitylation and proteolytic cleavage of Gli3 into the repressor form
Gli3R. These events lead to the repression of the Hh pathway and inhibition
of cell proliferation and tumor growth
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Uncropped scans of the most important blots are reported in Supplementary
Figs. 10 and 11.
In vivo ubiquitylation assay. MEFs were lysed with denaturing buffer (1% SDS,
50 mM Tris-HCl at pH 7.5, 0.5 mM EDTA, 1 mM DTT) to disrupt protein-protein
interactions. Lysates were then diluted 10 times with NETN lysis buffer and sub-
jected to immunoprecipitation with anti-βTrCP (Santa Cruz Biotechonology)
overnight at 4 °C with rotation. The immunoprecipitated proteins were then
washed five times with the NETN lysis buffer, resuspended in sample loading
buffer, boiled for 5 min, resolved in SDS-PAGE and then subjected to immunoblot
analysis. Polyubiquitylated forms were detected using mouse anti-HA from Santa
Cruz Biotechnology.
mRNA expression analysis. Total RNA was extracted using TRIzol reagent
(Thermo Fisher Scientific) and reverse-transcribed with SensiFASTcDNA Synth-
esis Kit (Bioline Reagents Limited, London, UK). Quantitative real time PCR
(qPCR) analysis of ERAP1, βTrCP, Gli1, Gli2, Ptch1, Hip1, CyclinD2, N-Myc, Oct4,
and Nanog mRNA expression was performed using the ViiATM 7 Real-Time PCR
System (Life Technologies). Standard qPCR thermal cycler parameters were used to
amplify a reaction mixture containing cDNA template, SensiFASTTM Probe Lo-
ROX mix (Bioline Reagents Limited) and Taqman Gene Expression Assays
(Thermo Fisher Scientific). The average of three threshold cycles was used to
calculate the amount of transcript in each sample amplificated in triplicate (using
SDS version 2.3 software). mRNA quantification was calculated as the ratio of the
sample quantity to the calibrator quantity expressed in arbitrary units. Data were
normalized with the endogenous controls (GAPDH and HPRT) and expressed as
the fold change respect to the control sample value.
BrdU incorporation and MB neurosphere-forming assay. Cell proliferation was
evaluated by BrdU detection (Roche, Welwyn Garden City, UK). Briefly, cells were
pulsed 24 h with BrdU and then fixed and permeabilized with 4% paraformalde-
hyde and 0.2% Triton X-100, respectively. Nuclei were counterstained with
Hoechst reagent and BrdU detection was performed according to the manu-
facturer’s instructions. At least 500 nuclei were counted in triplicate, and the
number of BrdU-positive nuclei was recorded. To determine the growth rate of
viable cells, a trypan blue count was performed after a treatment period of 24, 48
and 72 h with Leu-SH at the indicated dose.
For the neurosphere-forming assay, cells were plated at clonal density (1–2
cells/mm2) into 96-well plates and treated with Leu-SH at the indicated
concentration.
Cell viability assay in SHH-MB PDX model. Patient-derived xenograft (PDXs)-
ICN-MB 12 was generated from primary human SHH- MB sample diagnosed at
the Children’s Necker Hospital in Paris and transplanted into the subscapular
fatpad of immunocompromised NOD/SCID mice63. Human sample for xenograft
studies was obtained under written informed consent and ethical approved by the
Internal Review Board of the Necker Sick Children’s Hospital, Paris, France.
Tumor cells from PDX model were purified and cultured63. For culture experi-
ments, 75,000 tumor cells per well were plated in 96-well plates, pre-coated with
poly-D-lysine (EMD Millipore, Billerica, MA) and Matrigel (BD Biosciences, San
Jose, CA). Cells were grown in Neurobasal medium with B27 supplement, 2 mM
glutamine, penicillin/streptomycin (all from Thermo Fisher Scientific), bovine
serum albumin, and 0.45% D-glucose (both from Sigma Aldrich). The next day,
cultured tumor cells were treated with different concentrations of Leu-SH plus 0.1
M DTT or water plus 0.1 M DTT for the control. For the Incucyte experiment, cells
were treated with 0.3 µg/ml of propidium iodide (PI, Sigma Aldrich). Then, the
plates were scanned for phase contrast and PI staining every 3 h during 72 h using
the IncuCyte imager with a 4X objective (Essen BioScience). Proliferation was
measured using quantitative kinetic processing metrics from time-lapse image
acquisition and showed as percentage of culture confluence over time. For the PI
staining, which allowed to fluorescently stain the nuclear DNA of cells that have
lost plasma membrane integrity, the percentage of PI positive cells (corresponding
to red object confluence) was divided by the phase object confluence percentage for
each well, thus indicating the level of dead cells in each well. For the CellTiter-Glo®
Luminescent Cell Viability Assay the cell viability was examined after 72 h of
treatment according to the manufacturer’s instructions (Promega Corporation,
Madison, WI, USA). Results were expressed as luciferase fluorescence and repre-
sented the mean ± S.D. of three experiments, each performed in triplicate.
Animal studies. For allograft experiment, spontaneous MB from Math1-cre/PtcC/
C mice57 was isolated, minced and pipetted to obtain a single-cell suspension. Equal
amounts of cells (2 × 106) were injected s.c. at the posterior flank of NSG (Charles
River Laboratories, Lecco, Italy). Tumors were grown until a median size of
~150 mm3. Animals were randomly divided in two groups (n= 6) and intratu-
morally injected every other day with (0.528 μmol/Kg) Leu-SH and/or 0.1 M DTT
for 18 days. Primary cells of spontaneous MB from Math1-cre/PtcC/C mice were
infected for 72 h with purified lentiviral particles encoding short hairpin RNA
targeting murine ERAP1 (shERAP1) or a control non-targeting sequence
(shCTRL). Equal amounts of cells (2 × 106) were injected s.c. at the posterior flank
of NSG mice. GCPs from the cerebella of postnatal (P) day P5-P7 Math1-cre/PtcC/
C mice were infected with purified lentiviral particles encoding ERAP1 or an empty
GFP vector. Equal amounts of cells (2 × 106) were injected s.c. at the posterior flank
of NSG mice. Cells were resuspended in an equal volume of culture medium and
Matrigel (BD Biosciences, Heidelberg, Germany) before the s.c. injection. After
the injection, tumor growth was monitored and measured with caliper. Changes
in tumor volume were evaluated with the formula (length × width) × 0.5 ×
(length+width).
For orthotopic allograft model, adult NSG mice were anesthetized by i.p.
injection of ketamine (10 mg/kg) and xylazine (100 mg/kg). The posterior cranial
region was shaved and placed in a stereotaxic head frame and primary cells of
spontaneous MB from Math1-cre/PtcC/C mice freshly isolated or infected for 72 h
with purified lentiviral particles encoding murine shERAP1 or shCTRL were
stereotaxically implanted into the cerebellum (2 × 105/3 µl) according to the atlas of
Franklin and Paxinos coordinates. After injection, at an infusion rate of 1 µl/min,
the cannula was kept in place for 5 min and then the skin was closed using metallic
clips. After 10 days following tumor implantation, the animals were randomly
divided into two groups (n= 6) and treated i.p. every other day with Leu-SH 1 mg/
Kg or vehicle only. After 25 days of treatment, animals were sacrificed and brains
were fixed in 4% formaldehyde and paraffin embedded. Mice implanted with the
tumor cells silenced for ERAP1 were sacrificed after six weeks. Tumor volume
calculation was performed on serial 40 coronal sections of 2 µm after H&E staining
every 40 µm of brain slice. A microscope (Axio Imager M1 microscope; Leica
Microsystems GmbH, Wetzlar, Germany) equipped with a motorized stage and
Image Pro Plus 6.2 software was used to evaluate tumor area of each slide and the
tumor volume was calculated by the formula: tumor volume= sum of measured
area for each slice × slice thickness × sampling frequency59.
For Gfap-Cre/Ptcfl/fl mice injection, symptomatic Gfap-Cre/Ptcfl/fl mice were
randomly divided into two groups (n= 5) and injected s.c under the scruff with
(0.528 μmol/Kg) Leu-SH and/or 0.1 M DTT for two days. Tumor masses were
analyzed by qRT-PCR and immunoblotting.
For survival analysis, P21 Math-cre/PtcC/C mice were randomized to receive
either Leu-SH (1 mg/Kg) or vehicle every other day by i.p. injection. Statistical
analysis was performed by MedCalc software.
For xenograft experiment, Daoy cells were infected with lentiviral particles
encoding either short hairpin RNA targeting human ERAP1 (shERAP1) or a
control non-targeting sequence (shCTRL). Equal amounts (2 × 106) of cells were
injected s.c. at the posterior flank of NSG mice.
Patient-derived xenograft (PDXs)-ICN-MB 12 was isolated, minced and
purified. Cells (3 × 106) were injected s.c. at the posterior flank of NSG mice.
Tumors were grown until a median size of ~150 mm3. Animals were randomly
divided in two groups (n= 6) and intratumorally injected with (0.528 μmol/Kg)
Leu-SH and/or 0.1 M DTT for 18 days. Cells were resuspended in an equal volume
of culture medium and Matrigel before the s.c. injection. Tumor growth was
monitored and measured with caliper. Changes in tumor volume were evaluated
with the formula (length x width) x 0.5 × (length+width).
All animal protocols were approved by local ethic authorities (Ministry of
Health) and conducted in accordance with Italian Governing Law (D.lgs 26/2014).
Immunohistochemistry. Formaldehyde-fixed paraffin-embedded (FFPE) tissues
and frozen OCT-embedded tissues were cut into 4μm sections for Gli1, Ki67,
cleaved Caspase-3, NeuN, and ERAP1 immunohistochemical staining. FFPE slides
were deparaffinized and subjected to heat-induced antigen retrieval at low or high
pH buffer, whereas frozen tissues were fixed in 4% paraformaldehyde. Slides were
blocked for 30 min with 5% PBS/BSA. FFPE slides were incubated with monoclonal
antibodies against Gli1, Ki67, cleaved Caspase-3, NeuN, whereas cryostat sections
were incubated with monoclonal antibody ERAP1 (4D2, 50 mg/ml overnight 4 °C).
This step was followed by incubation for 20 min with secondary antibodies coupled
with peroxidase (Dako). Bound peroxidase was detected with diaminobenzidine
(DAB) solution and EnVision FLEX Substrate buffer containing peroxide (Dako).
Cell quantification was performed on collected sections using the imaging software
NIS-Elements BR 4.00.05 (Nikon Instruments Europe B.V., Italy). Images were
captured by HistoFAXS software (TissueGnostics GmbH, Vienna, Austria) at 20x
magnification. Tumor regions were analyzed with HistoQuest software (TissueG-
nostics) for automatic color separation and quantification. Expression levels were
evaluated as stained area per mm2.
Immunofluorescence. After 24 h of transfection, cells were fixed for 15 min in 4%
paraformaldehyde, treated with glycine 1 M for 15 min to saturate the residual site
of paraformaldehyde, permeabilized for 8 min in 0.2% Triton X-100 and blocked
with 3% BSA for 30 min. Cells were then labeled with primary antibody for 1 h,
followed by staining with secondary antibodies specific for rabbit or mouse (Alexa
Fluor 488, A21206, and Alexa Fluor 546, A11030, respectively, Life Technologies).
Single plane confocal images were acquired using an inverted Olympus iX73
microscope equipped with an X-light Nipkow spinning-disk head (Crest Optics,
Rome, Italy) and Lumencor Spectra X Led illumination. Images were collected
using a CoolSNAP MYO CCD camera (Photometrics, Tucson, AZ, USA) and
MetaMorph Software (Molecular Device, Sunnyvale, CA, USA) with a x60 oil
objective.
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Statistical analysis. Statistical analysis was performed using the StatView
4.1 software (Abacus Concepts, Berkeley, CA, USA). For all experiments, P values
were determined using two-tailed Student’s t-test and statistical significance was set
at P < 0.05. Results are expressed as mean ± S.D. from an appropriate number of
experiments (at least three biological replicas). For IncuCyte experiments, statistical
significance was determined with GraphPad Prism software (version 6.0, La Jolla,
CA, USA). Data were analyzed with the Two-way ANOVA test and given as mean
± SD. For survival analysis statistical significance was calculated with Logrank-test
performed by MedCalc software.
Data availability
All data in this study are available within the Article and Supplementary Information or
from the corresponding author on reasonable request.
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